Oncology News | pharmaphorum

News

Pfizer builds on Braftovi bowel cancer OK with survival data

Pfizer's Braftovi - just approved by the FDA as a first-line treatment for colorectal cancer based on response data - also extends patient survival.

News

Boost to Enhertu's prospects as FDA clears Roche diagnostic

Roche gets the first FDA approval for a diagnostic test for HER2-ultralow breast cancer, now on the label of AstraZeneca and Daiichi Sankyo's Enhertu.

News

Enhertu gets first okay for HER2-ultralow breast cancer

Enhertu gets much-anticipated new FDA approval in breast cancer that expands its label and makes it an earlier option in the treatment pathway.

News

Italian decision sets up launch of Oncopeptides' Pepaxti

Oncopeptides hopes to reignite growth in multiple myeloma drug Pepaxti after getting reimbursement approval in Italy.

News

Martin Olin has been named chief executive of the UK start-up

UK biotech Swarm lands with a T-cell therapy mission

UK firm Swarm Oncology launches with a T-cell therapy platform to treat solid tumours, with a Resolution Therapeutics co-founder in the pilot seat.

News

Ascentage raises $126m in first biotech IPO of 2025

China's Ascentage completes the first US biotech IPO of 2025, raising $126m for its pipeline of small-molecule cancer drugs.

Pfizer builds on Braftovi bowel cancer OK with survival data

Boost to Enhertu's prospects as FDA clears Roche diagnostic

Enhertu gets first okay for HER2-ultralow breast cancer

Italian decision sets up launch of Oncopeptides' Pepaxti

UK biotech Swarm lands with a T-cell therapy mission

Ascentage raises $126m in first biotech IPO of 2025

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks